ArticleFrontiers in oncology2020

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.

Jianhui Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.